Table 2.
Multivariable models evaluating factors associated with levels of AST and ALT among TM and CM study participants
|
AST
|
ALT
|
|||
|---|---|---|---|---|
| Parameter of interest | Difference (%) | 95% CI | Difference (%) | 95% CI |
| Gender identity (TM vs CM) | −13 | −20, −5 | −27 | −31, −23 |
|
| ||||
| Site (KPNC vs other) | 1 | −4, 6 | 8 | 5, 12 |
|
| ||||
| Age group (y) vs 18–25 | ||||
|
| ||||
| 26–35 | 3 | −3, 9 | 9 | 5, 15 |
|
| ||||
| 36–45 | 11 | 3, 17 | 13 | 8, 19 |
|
| ||||
| 46–55 | 1 | −5, 8 | 1 | −3, 6 |
|
| ||||
| 56+ | −1 | −7, 6 | −8 | −12, −3 |
|
| ||||
| Race/ethnicity (vs NHW) | ||||
|
| ||||
| Non-Hispanic Black | 3 | −5, 11 | −7 | −11, −2 |
|
| ||||
| Hispanic | 3 | −3, 9 | 9 | 6, 14 |
|
| ||||
| Asian/Pacific Islander | −4 | −10, 4 | 3 | −1, 8 |
|
| ||||
| Other/Unknown | −9 | −19, 2 | 4 | −3, 12 |
|
| ||||
| Body mass index (kg/m2) ≥25.0 vs <25.0 | 7 | 3, 13 | 30 | 26, 34 |
|
| ||||
| Alcohol use/abuse (yes vs no) | 19 | 13, 25 | 11 | 6, 14 |
|
| ||||
| Time (10-d increments) | ||||
|
| ||||
| Pre-GAHT | −2 | −7, 2 | −10 | −12, −7 |
|
| ||||
| Post-GAHT | −7 | −17, 5 | 1 | −6, 8 |
|
| ||||
| Pre-GAHT × gender identity | 21 | 1, 45 | 26 | 12, 42 |
|
| ||||
| Post-GAHT × gender identity | 34 | −15, 110 | 63 | 26, 114 |
|
| ||||
| Calculated adjusted average 10-d change (%) | ||||
|
| ||||
| TM pre-GAHT | 18 | −1, 40 | 14 | 2, 28 |
|
| ||||
| TM post-GAHT | 47 | 4, 108 | 89 | 54, 131 |
|
| ||||
| CM pre-GAHT | −2 | −7, 3 | −10 | −13, −6 |
|
| ||||
| CM post-GAHT | −9 | −17, 0 | −8 | −13, −4 |
|
| ||||
| Ratio-of-ratios for 10-d change among TM (post- vs pre-GAHT) | 1.25 | 0.81, 1.92 | 1.65 | 1.28, 2.14 |
|
| ||||
| Ratio-of-ratios for post-GAHT 10-d change (TM vs CM) | 1.61 | 1.13, 2.31 | 2.06 | 1.67, 2.54 |
ALT = alanine aminotransferase; AST = aspartate aminotransferase; CI = confidence interval; CM = cisgender males; GAHT = gender affirming hormone therapy; KPNC = Kaiser Permanente Northern California; TM = transmasculine, NHW = non-Hispanic White.